These announcements are in line with Croda Pharma’s strategy to “Empower Biologics Delivery” and follows news on investments, earlier this year, to expand Croda Pharma’s global manufacturing capabilities to enable the next generation vaccines and therapeutic drugs.
The USFDA had classified Strides Puducherry facility as OAI in May 2019 followed by issuing a warning letter to this site in July 2019.
First clinical trial reporting results of an mRNA therapeutic for intracellular protein replacement
Leading Research-driven Pharma Company Combats Antibiotic Resistance and Demonstrates Innovation in Medical Solutions
These initiatives aim to improve access to healthcare for rare disease patients
Farxiga is expected to have such a strong influence on the market due to the impressive results
This latest audit re-emphasizes Hikal's commitment towards maintaining the best in class quality, compliance and regulatory standards across our manufacturing sites
The Niti Aayog and the DoP had listed a few factors that were leading to a 10-15% disability factor to be globally competitive
The facility will have a capacity to manufacture upto 3 million tubes monthly
VEOZAH is first-in-class treatment option to reduce the frequency and severity of moderate to severe VMS due to menopause
Subscribe To Our Newsletter & Stay Updated
